Sodium dichloroacetate (DCA), a small-molecular-weight drug, is capable to shift the tumor metabolism by reactivating the oxidative phosphorylation in the mitochondria. As a consequence, apoptosis resistance in cancer cells decreased. Numerous studies have been performed in cell lines and animal models, to unveil its efficacy as an antitumor drug. It is also being studied in patients with different types of tumors, with a variety of doses and administration schedules. Even so, the lack of controlled studies makes the safety profile a concern. This scoping review aims to explore the existing scientific literature to provide an overview of the use of DCA (any dose, frequency, or route of administration) in adults with cancer. The search will be performed in MEDLINE/PubMed, and LILACS databases. Additional data sources will be consulted. Two reviewers will screen all identified records for relevance, and chart the data using a data charting form. Findings will be reported according to PRISMA for Scoping Reviews (PRISMA-ScR). No quality assessment will be performed.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present work are contained in the manuscript